288 related articles for article (PubMed ID: 29507077)
1. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
[TBL] [Abstract][Full Text] [Related]
3. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S; O'Connor OA; Pro B; Trümper L; Iyer S; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Menne T; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Zinzani PL; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Illidge T
Ann Oncol; 2022 Mar; 33(3):288-298. PubMed ID: 34921960
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Svoboda J; Bair SM; Landsburg DJ; Dwivedy Nasta S; Nagle SJ; Barta SK; Khan N; Filicko-O'Hara J; Gaballa S; Strelec L; Chong E; Mitnick S; Waite TS; King C; Ballard H; Youngman M; Gerson J; Plastaras JP; Maity A; Bogusz AM; Hung SS; Nakamura H; Nejati R; Steidl C; Lim M; Ruella M; Schuster SJ
Haematologica; 2021 Jun; 106(6):1705-1713. PubMed ID: 32414850
[TBL] [Abstract][Full Text] [Related]
7. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ; Horwitz SM; Advani R; Christensen JH; Domingo-Domenech E; Rossi G; Morschhauser F; Alpdogan O; Suh C; Tobinai K; Shustov A; Trneny M; Yuen S; Zinzani PL; Trümper L; Ilidge T; O'Connor OA; Pro B; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Iyer S
Blood Adv; 2022 Oct; 6(19):5550-5555. PubMed ID: 35470385
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
11. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
Hong J; Johnson WT; Kartan S; Gonsalves AS; Fenkel JM; Gong JZ; Porcu P
Curr Oncol; 2021 Dec; 28(6):5067-5072. PubMed ID: 34940065
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
[TBL] [Abstract][Full Text] [Related]
13. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
15. ECHELON-2 - brentuximab raises PTCL outcomes to new levels.
Killock D
Nat Rev Clin Oncol; 2019 Mar; 16(3):145. PubMed ID: 30602757
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
Feldman T; Zou D; Rebeira M; Lee J; Fanale M; Manley T; Rao S; Feliciano J; Harris M; Kansal A
Am J Manag Care; 2020 Feb; 26(2):e41-e49. PubMed ID: 32059099
[TBL] [Abstract][Full Text] [Related]
17. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Fenton K; Huebner D; Pinelli JM; Kennedy DA; Shustov A
Blood; 2017 Dec; 130(25):2709-2717. PubMed ID: 28974506
[TBL] [Abstract][Full Text] [Related]
18. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
[TBL] [Abstract][Full Text] [Related]
19. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
Bartlett NL; Chen R; Fanale MA; Brice P; Gopal A; Smith SE; Advani R; Matous JV; Ramchandren R; Rosenblatt JD; Huebner D; Levine P; Grove L; Forero-Torres A
J Hematol Oncol; 2014 Mar; 7():24. PubMed ID: 24642247
[TBL] [Abstract][Full Text] [Related]
20. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]